Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0001213900-25-020723
Filing Date
2025-03-05
Accepted
2025-03-05 16:15:54
Documents
4
Effectiveness Date
2025-03-05

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0232843-s8_protara.htm S-8 53455
2 OPINION OF SULLIVAN & CROMWELL LLP ea023284301ex5-1_protara.htm EX-5.1 5319
3 CONSENT OF ERNST & YOUNG LLP ea023284301ex23-1_protara.htm EX-23.1 1827
4 FILING FEE TABLE ea021048001ex-fee_protara.htm EX-FILING FEES 13088
  Complete submission text file 0001213900-25-020723.txt   74946
Mailing Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010
Business Address 345 PARK AVENUE SOUTH 3RD FLOOR NEW YORK NY 10010 646-844-0337
Protara Therapeutics, Inc. (Filer) CIK: 0001359931 (see all company filings)

EIN.: 204580525 | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-285568 | Film No.: 25711244
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)